Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  hydroxyurea
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-12 of 12 for your search:
Start Over
Trial Comparing Two Protocols of re Irradiation in an Irradiated Area for Carcinoma of the Upper Aerodigestive Tract
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: CSET 1542-JANORL2, 2009-017047-34, NCT01211938
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: GCO 09-1300-00002, P01CA108671, MPD-RC 112, NCT01259856
A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: daliah2011, NCT01387763
Randomized Phase III Study of Decitabine +/- Hydroxyurea (HY) Versus HY in Advanced Proliferative CMML
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GFM-DAC-CMML, NCT02214407
Treatment of Acute Leukemia Relapse After Allotransplantation
Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 to 90
Sponsor: Other
Protocol IDs: Allo-Relapse-2011, NCT01369368
Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IV Head and Neck Cancer
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02009, A091101, N01CM62201, U10CA180821, U10CA031946, NCT01711541
Reduced Intensity Conditioning in Patients Aged =35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT
Phase: Phase II
Type: Treatment
Status: Active
Age: 2 months to 30 years
Sponsor: Other
Protocol IDs: RIC for HSCT in NMD, PRO13100018, NCT01962415
Phase II of Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 20090166, NCT01964755
Selinexor (KPT-330) in Older Patients With Relapsed AML
Phase: Phase II
Type: Treatment
Status: Active
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: KCP-330-008, NCT02088541
Trabectedin for Recurrent Grade II/III Meningioma
Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-1320, NCT02234050
Nab-paclitaxel and Carboplatin Followed by Response-Based Local Therapy in Treating Patients With Stage III or IV HPV-Related Oropharyngeal Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: IRB14-0639, NCI-2014-01867, P30CA014599, NCT02258659
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin Followed By Chemoradiation in Treating Patients With Recurrent Head and Neck Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 12-1554, NCI-2012-02179, NCT01847326
Start Over